Published in Cardiovascular Business Week, March 3rd, 2009
2008 minimally invasive product revenues of $19.8 million up 38%
2008 international revenues of $8.3 million up 27%
25 patients enrolled to-date in EXCLUDE clinical trial
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, announced revenues for 2008 of $55.3 million and quarterly revenues of $12.1 million for its fourth quarter 2008. The net loss per share for 2008 improved 14.3% to $0.72.
As anticipated, the fourth quarter of 2008 presented several...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.